Ellis Greenhalgh Net Worth

Ellis Greenhalgh biography

Dr. Ellis Skott Greenhalgh Ph.D. serves as Chief Technology Officer of the Company. Dr. Greenhalgh has served as our Chief Technology Officer since December 2016, and as our Vice President of Research and Development from January 2013 through November 2016. Previously, Dr. Greenhalgh served as Chief Technology Officer at Stout Medical Group LP and US Biodesign Inc. Dr. Greenhalgh received his Doctor of Philosophy degree in Fiber and Polymer Science and his Master’s degree in Textile Engineering from North Carolina State University, and his Bachelor of Science degree in Mechanical Engineering is from Drexel University.

What is the salary of Ellis Greenhalgh?

As the Chief Technology Officer of TELA Bio, the total compensation of Ellis Greenhalgh at TELA Bio is $844,917. There are 2 executives at TELA Bio getting paid more, with Antony Koblish having the highest compensation of $2,399,600.

How old is Ellis Greenhalgh?

Ellis Greenhalgh is 52, he's been the Chief Technology Officer of TELA Bio since 2017. There are 11 older and 4 younger executives at TELA Bio. The oldest executive at TELA Bio, Inc. is Maarten Persenaire, 63, who is the Co-Founder, Chief Medical Officer.

What's Ellis Greenhalgh's mailing address?

Ellis's mailing address filed with the SEC is C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN, PA, 19355.

Insiders trading at TELA Bio

Over the last 5 years, insiders at TELA Bio have traded over $4,222,376 worth of TELA Bio stock and bought 4,343,227 units worth $46,898,981 . The most active insiders traders include Management Inc. Opaleye, Investments, Lpwong Roderic... e Advisors Llc Orbi Med Capit.... On average, TELA Bio executives and independent directors trade stock every 18 days with the average trade being worth of $139,070. The most recent stock trade was executed by Advisors Llc Orbi Med Capit... on 28 June 2024, trading 428,300 units of TELA stock currently worth $2,021,576.

What does TELA Bio do?

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

TELA Bio executives and stock owners

TELA Bio executives and other stock owners filed with the SEC include:

• Antony Koblish,
  President, Chief Executive Officer, Co-Founder, Director
• Maarten Persenaire,
  Co-Founder, Chief Medical Officer
• Ellis Greenhalgh,
  Chief Technology Officer
• Antony Koblish,
  Co-founder, Pres, CEO & Director
• Dr. E. Skott Greenhalgh Ph.D.,
  Chief Technology Officer
• kurt Azarbarzin,
  Independent Director
• Vince Burgess,
  Independent Director
• Federica OBrien,
  Independent Director
• Adele Oliva,
  Independent Director
• Lisa Colleran,
  Independent Director
• Peter Murphy,
  Chief Commercial Officer
• Nora Brennan,
  Chief Financial Officer
• Douglas Evans,
  Independent Chairman of the Board
• D. Taylor Ocasio,
  Gen. Counsel
• Francis Michael Conway,
  VP of Fin., Treasurer & Assistant Sec.
• Peter C. Murphy,
  Chief Commercial Officer
• Paul Talmo,
  Chief Strategic Officer
• Michael Leonard,
  Sr. VP of Operations, Quality & Regulatory
• Jennifer Lou Armstrong,
  Sr. VP of HR
• Christopher H. Smith,
  Sr. VP of Sales
• Megan Smeykal,
  VP, Corp. Controller, Chief Accounting Officer & Principal Accounting Officer
• Roberto E. Cuca J.D.,
  CFO & COO
• Bio Ventures Ii Lp Quaker B...,
  
• Ronald J. Jr.Pacira Bio Sci...,
  
• Ashley Friedman,
  Director
• Investments, Lpwong Roderic...,
  
• Matt Zuga,
  Director
• Federica F. O'brien,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Healthcare Partners Fund 2,...,
  
• John Nosenzo,
  Director
• Roberto Cuca,
  COO and CFO
• Megan Smeykal,
  Chief Accounting Officer
• Paul Talmo,
  Chief Technology Officer
• Management Inc. Opaleye,
  
• Jeffrey Blizard,
  Director
• Gregory A. Firestone,
  Chief Commercial Officer